par Amato, Ottavia;Giannopoulou, Nefeli;Ignatiadis, Michail 
Référence NPJ breast cancer, 10, 1, 21
Publication A Paraître, 2024-12
Référence NPJ breast cancer, 10, 1, 21
Publication A Paraître, 2024-12
Article révisé par les pairs
| Résumé : | Following the first characterization of circulating tumor DNA (ctDNA) in the 1990s, recent advances led to its introduction in the clinics. At present, the European Society Of Medical Oncology (ESMO) recommendations endorse ctDNA testing in routine clinical practice for tumor genotyping to direct molecularly targeted therapies in patients with metastatic cancer. In studies on metastatic breast cancer, ctDNA has been utilized for treatment tailoring, tracking mechanisms of drug resistance, and for predicting disease response before imaging. We review the available evidence regarding ctDNA applications in metastatic breast cancer. |
